1
项与 HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine(Fukushima Medical University) 相关的临床试验Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma
The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.
100 项与 HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine(Fukushima Medical University) 相关的临床结果
100 项与 HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine(Fukushima Medical University) 相关的转化医学
100 项与 HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine(Fukushima Medical University) 相关的专利(医药)
100 项与 HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine(Fukushima Medical University) 相关的药物交易